Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2015 | Treatment of relapsed multiple myeloma: New combinations, new generations, new targets

Keith Stewart • 4 Dec 2015
ASH 2015
Multiple Myeloma Antibodies Carfilzomib Daratumumab Elotuzumab Ixazomib Panobinostat

At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Keith Stewart, MB, ChB, from Mayo Clinic, Scottsdale, AZ, summarises recently approved treatment options for patients with relapsed multiple myeloma, including proteasome inhibitors, carfilzomib and ixazomib; histone deacetylase (HDAC) inhibitor, panobinostat; and monoclonal antibodies, CS1-targeting elotuzumab and CD38-targeting daratumumab.

More from Keith Stewart

The future of myeloma therapy
Brian Walker et al. • 15 Apr 2023
Day 2 wrap-up: pushing myeloma boundaries 10:38
Day 2 wrap-up: pushing myeloma boundaries
Gareth Morgan et al. • 27 Mar 2022
Day 1 highlights: peripheral blood MRD, AB amyloid treatment, single-cell & metabolomics 11:10
Day 1 highlights: peripheral blood MRD, AB amyloid treatment, single-cell & metabolomics
Faith Davies et al. • 26 Mar 2022
Immunotherapy in myeloma – where are we? 3:09
Immunotherapy in myeloma – where are we?
Keith Stewart • 30 Apr 2020

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals